Enveric Biosciences Inc reports results for the quarter ended December 31 - Earnings Summary

• Enveric Biosciences Inc (ENVB.OQ) reported a quarterly adjusted loss of $4.80​​ per share for the quarter ended December 31, higher than the same quarter last year, when the company reported EPS of $-22.05. The lone analyst forecast for the quarter was for a loss of 23 cents per share.

• Reported revenue was zero​; analysts expected zero.

• Enveric Biosciences Inc’s reported EPS for the quarter was a loss of $4.80​.

• The company reported a quarterly loss of $3.16 million.

• Enveric Biosciences Inc shares had fallen by 70.2% this quarter. FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 96.2% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company. RECOMMENDATIONS

• The current average analyst rating on the shares is “buy” and the breakdown of recommendations is 1 “strong buy” or “buy,” no “hold” and no “sell” or “strong sell.” The average consensus recommendation for the biotechnology & medical research peer group is also “buy”

• Wall Street’s median 12-month price target for Enveric Biosciences Inc is $54.80 This summary was machine generated from LSEG data March 28 at 11:00 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,

MISSED

Dec. 31 2024 -0.23 -4.80 Missed

Sep. 30 2024 -7.80 -3.60 Beat

Jun. 30 2024 -8.25 -3.75 Beat

Mar. 31 2024 -11.62 -9.15 Beat